Cargando…
Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis
Herpes simplex virus type-1 (HSV-1) can cause severe ocular infection and blindness. We have previously shown that the HSV-1 VC2 vaccine strain is protective in mice and guinea pigs against genital herpes infection following vaginal challenge with HSV-1 or HSV-2. In this study, we evaluated the effi...
Autores principales: | Naidu, Shan K., Nabi, Rafiq, Cheemarla, Nagarjuna R., Stanfield, Brent A., Rider, Paul J., Jambunathan, Nithya, Chouljenko, Vladimir N., Carter, Renee, Del Piero, Fabio, Langohr, Ingeborg, Kousoulas, Konstantin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004361/ https://www.ncbi.nlm.nih.gov/pubmed/32027675 http://dx.doi.org/10.1371/journal.pone.0228252 |
Ejemplares similares
-
A Single Intramuscular Vaccination of Mice with the HSV-1 VC2 Virus with Mutations in the Glycoprotein K and the Membrane Protein UL20 Confers Full Protection against Lethal Intravaginal Challenge with Virulent HSV-1 and HSV-2 Strains
por: Stanfield, Brent A., et al.
Publicado: (2014) -
Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With γδT Cell Intracorneal Infiltration
por: Nabi, Rafiq, et al.
Publicado: (2021) -
Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1(VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF
por: Clark, Carolyn M., et al.
Publicado: (2023) -
The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer
por: Nabi, Rafiq, et al.
Publicado: (2023) -
Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2022)